Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 25

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 25
---
 other party thereto except for (i) liability for any willful breach of the Merger Agreement prior to such termination and (ii) in the event that NLS terminates the Merger Agreement to enter into a definitive agreement providing for a Parent Superior Proposal, then NLS shall pay to Kadimastem an amount equal to $10,000,000 plus certain NLS operating and transaction expenses. Corporate Information Our registered office and principal executive office are located at The Circle 6, 8058 Zurich, Switzerland. Our telephone number in Switzerland is +41.44.512.2150. Our website address is https://nlspharma.com. The information contained on, or that can be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. The SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC’s website at http://www.sec.gov.

<div align='center'>11</div>

THE OFFERING

| Issuer                                                     |     | NLS Pharmaceutics Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Securities offered by the Selling Shareholder              |     | Up to 5,000,000 Common Shares consisting of: (i) 192,308 Commitment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 Shares and (ii) up to 4,807,692 Common Shares that we may sell to the Selling Shareholder under the Purchase Agreement from time-to-time,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 based on an assumed price per share of $2.21, which is the last reported sales price of our Common Shares on Nasdaq on September 22, 2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Common Shares issued and outstanding prior to the offering |     | 4,252,025 Common Shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Common Shares to be outstanding after this offering (1)    |     | 9,252,025 Common Shares, assuming the sale of a total of 5,000,000 Common Shares to the Selling Shareholder pursuant to the Purchase Agreement (at an assumed price per share of $2.21, which is the last reported sales price of our Common Shares on Nasdaq on September 22, 2025).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Use of proceeds